PAVmed, a pre-revenue medical device company developing various products, raised $5.3 million by offering 1.06 million units at $5, as expected. At that price, the company commands a post-IPO market cap of $67 million. PAVmed plans to list on the Nasdaq under the symbol PAVMU. Benchmark acted as a lead manager on the deal.
Because the deal was a unit offering marketed on a "best efforts" basis, PAVmed is not included in our IPO stats.
